13,14-Dihydro-15-keto-prostaglandin F2 alpha in patients with urogenital tumors.
13,14-Dihydro-15-keto-prostaglandin F2 alpha (13,14-DHK-PGF2 alpha) represents a stable product of degradation after pulmonary flow and it is shown to be reliably measured by radioimmunoassay. In patients with urogenital tumors, serum levels of 13,14-DHK-PGF2 alpha are distinctly elevated when compared to a control group. The rate of synthesis of this compound in urogenital tumors, however, appears to be different.
D000230:Adenocarcinoma / Q000097:blood; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood; D011460:Prostaglandins F / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood; D011863:Radioimmunoassay; D013736:Testicular Neoplasms / Q000097:blood; D001749:Urinary Bladder Neoplasms / Q000097:blood; D014565:Urogenital Neoplasms / Q000097:blood*
D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D015237:Dinoprost